ELIXIRON IMMUNOTHERAPEUTICS INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Develop innovative therapies for cancer and immunological diseases.
The content above was translated by Ai
Founded Year
2017
Unified Business No.
52625245
Status
Active
Number of Employees
0
Total Paid-in
Capital
621,180,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics from phage display and single human B cell cloning platforms, to develop innovative therapies for cancer and immunological diseases.
The content above was translated by Ai
